What is REMODULIN?
REMODULIN® (treprostinil sodium) Injection is a stable analogue of prostacyclin which has a half-life of between two and four hours and can be safely administered by a continuous subcutaneous infusion, via a self-inserted subcutaneous catheter using a micro-infusion pump (an example of which is the MiniMed 407c) designed specifically for subcutaneous drug delivery.
How did REMODULIN develop?
Over the past six years United Therapeutics has taken REMODULIN (previously referred to as UT-15, 15AU81, and UNIPROST™) through a complete worldwide clinical development, treating over 1000 patients in the process. The result of this effort has been the approval of REMODULIN by the FDA for the treatment of Pulmonary Arterial Hypertension (PAH) in patients with NYHA Class II, III and IV symptoms to diminish symptoms associated with exercise. REMODULIN has been recently approved for use in Canada and Israel.
What are the specifics of REMODULIN?
Dosage and Administration
REMODULIN is supplied in 20 mL vials in concentrations of 1.0 mg/mL, 2.5 mg/mL, 5.0 mg/mL, and 10.0 mg/mL. REMODULIN is meant to be administered without further dilution.
REMODULIN is administered continuously by an infusion pump, through a small catheter placed under the skin. A doctor or nurse will give you detailed instructions regarding the correct placement and care of the catheter and use of the infusion pump to administer medication.
REMODULIN infusion rate will be determined by your physician, based on your weight and the concentration of REMODULIN used. You should not stop using REMODULIN or adjust the dosage without first talking to your doctor. All patients receiving REMODULIN should have access to a backup pump and pump supplies to avoid possible drug delivery interruptions.
Please refer to the REMODULIN package insert for complete prescribing information. (Requires the free Adobe Acrobat reader.)
Effectiveness of REMODULIN® in Treating PAH